|
Mar 19
|
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
|
|
Mar 19
|
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
|
|
Mar 18
|
Madrigal Pharmaceuticals Announces Proposed Public Offering
|
|
Mar 18
|
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 17
|
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
|
|
Mar 15
|
Wegovy and Zepbound Cast Shadow Over Madrigal’s Liver Drug
|
|
Mar 15
|
Geron, Madrigal Pharmaceuticals jump on good news from FDA
|
|
Mar 15
|
Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment
|
|
Mar 15
|
US STOCKS-Wall St slides as inflation woes dampen rate-cut bets
|
|
Mar 15
|
Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.
|
|
Mar 15
|
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|
|
Mar 15
|
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
|
|
Mar 14
|
Madrigal Stock Soars More Than 20% After FDA Approved First In MASH Treatment
|
|
Mar 14
|
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
|
|
Mar 14
|
Madrigal wins FDA approval of first drug for MASH
|
|
Mar 9
|
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
|
|
Mar 5
|
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
|
|
Mar 5
|
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
|